Skip to content

DM BIOMED DEVELOPMENT

Active Private limited companyfounded 2012active for 14 yearsRue des Montys 53, 4141 SprimontKBO/BCE: BE 0842.657.707

Timeline

28 events since 2012

Deadline for the 2026 accounts: 30-04-2027

2026
Annual accounts 2025 filed PDFmicro format · 65 days before the deadline
2025
Registered in the Peppol Directory Reachable for e-invoices through 0208:0842657707
Annual accounts 2024 filed PDFmicro format · 5 days before the deadline
2024
Back to profit net €20,879 The net result is €20,879, after one loss-making year.
Annual accounts 2023 filed PDFmicro format · 71 days before the deadline
2023
Weakest financial year net -€11,981 The net result drops to -€11,981, the lowest from 2012 to 2025. It recovers the following year.
Liquidity more than 7 times current ratio 14.43 The current ratio rises from 2.03 to 14.43. Short-term debt falls from €63,180 to €4,114.
Reappointment: MARÉCHAL Daniel Jean Henri Ghislain (director)General meeting of 29-06-20233 points ▸
  • General meeting, 29-06-2023
  • Director reappointment, MARÉCHAL Daniel Jean Henri Ghislain (director (not named in the articles))
  • Registered office clause, rue des Montys 53, 4141 Louveigné (Sprimont)
  • The deed holds 4 more points.

Open the deed in the Belgian Official Gazette

Annual accounts 2022 filed PDFmicro format · 25 days before the deadline
2022
Annual accounts 2021 filed PDFmicro format · 51 days before the deadline
2021
Annual accounts 2020 filed PDFmicro format · 81 days before the deadline
2020
Liquidity more than triples current ratio 12.96 The current ratio rises from 3.86 to 12.96. Short-term debt falls from €21,697 to €8,143.
Annual accounts 2019 filed PDFmicro format · 77 days before the deadline
2019
Annual accounts 2018 filed PDFfull format · 68 days before the deadline
2018
Liquidity more than doubled current ratio 15.90 The current ratio rises from 7.65 to 15.90. Short-term debt falls from €26,892 to €12,745.
Annual accounts 2017 filed PDFfull format · 80 days before the deadline
2017
Annual accounts 2016 filed PDFfull format · 59 days before the deadline
2016
Equity above €150,000 equity €160,057 ▲11.1% With a profit in every financial year since 2012, equity grows to €160,057.
Annual accounts 2015 filed PDFfull format · 86 days before the deadline
2015
Highest result from 2012 to 2025 net €46,218 ▲43.3% The net result of €46,218 is the highest of those years.
Liquidity more than doubled current ratio 7.86 The current ratio rises from 3.43 to 7.86. Short-term debt falls from €37,384 to €20,357.
Equity above €100,000 equity €144,053 ▲47.2% With a profit in every financial year since 2012, equity grows to €144,053.
Annual accounts 2014 filed PDFfull format · 78 days before the deadline
2014
Liquidity more than triples current ratio 3.43 The current ratio rises from 1.09 to 3.43. Short-term debt falls from €93,771 to €37,384.
Annual accounts 2013 filed PDFfull format · 70 days before the deadline
2013
Annual accounts 2012 filed PDFfull format · 22 days before the deadline
2012
Incorporation PDFpublished on 16-01-2012
First establishment Rue des Montys 53, Sprimont

Financial milestones sit on the financial year-end date, not the filing date.

Sources: Publications in the Belgian Official GazetteFilings with the National Bank

History

On 12 January 2012, DM BIOMED DEVELOPMENT was incorporated.1 Total assets went from €90,508 in 2019 to €124,632 in 2025.2

  1. 1KBO register
  2. 2National Bank, annual accounts 2019 and 2025

Next steps